APPROACH UNDER REVIEW: `rag`

SCENARIO ID: scenario_14
APP DESCRIPTION: SleepWell is an iOS/Android app that stages your sleep using phone microphone + accelerometer, and delivers a CBT-I (insomnia) coaching programme over 6 weeks. The coaching content is personalised by a small ML model based on user adherence and reported sleep. EU.

DEVELOPER PERSONA: Sleep researcher founder. Thinks scientifically but is new to medical-device regulation.

EXPECTED HERA DIMENSIONS (gold standard): P1.D1, P1.D5, P2.D1, P2.D2, P2.D3, P3.D1, P4.D5, P5.D1, P5.D2, P5.D4, P7.D1, P7.D3

TRANSCRIPT:
### USER
SleepWell is an iOS/Android app that stages your sleep using phone microphone + accelerometer, and delivers a CBT-I (insomnia) coaching programme over 6 weeks. The coaching content is personalised by a small ML model based on user adherence and reported sleep. EU.

### ASSISTANT
What is the primary medical purpose of the CBT-I coaching programme, and how does it align with the intended use described in the DiGA certification requirements? [card_diga_germany · p.0]

### USER
Our sleep staging is validated at about 80% agreement vs polysomnography in an in-lab study of N=50, which I'm proud of, but the 6-week CBT-I coaching programme itself has not been validated in-app — we're leaning on the published CBT-I literature, not our own efficacy trial.

### ASSISTANT
Does the lack of in-app validation for the CBT-I coaching programme pose a risk to meeting the "positive care effect" requirement under DiGA, and how might this affect your eligibility for permanent listing? [card_diga_germany · p.0]

### USER
Sleep staging runs on-device so tracking works offline overnight, but the personalised coaching and the digest upload need connectivity; we ship content and model updates through the normal app-store release cycle and we don't currently have a staged-rollback plan if an update misbehaves. Post-market we mostly rely on crash analytics and a monthly retention review.

### ASSISTANT
Does the reliance on crash analytics and monthly retention reviews for post-market monitoring meet the CRA's requirements for a vulnerability-handling and coordinated-disclosure process, and what steps are needed to align with the CRA's cybersecurity essential requirements? [card_cra · p.0]

### USER
Crash analytics + monthly retention review.

### ASSISTANT
Does the absence of a vulnerability-handling process, such as a Software Bill of Materials (SBOM) and a coordinated-disclosure policy, pose a risk under [P2.D3] "Post-Market Surveillance and Risk Management" of the HERA taxonomy, and what steps are needed to comply with the CRA's essential cybersecurity requirements? [card_cra · p.0]

### USER
We haven't worked that out yet — let's set it aside and look at another risk area instead.

### ASSISTANT
What is the potential risk to user privacy and data security under [P2.D4] "Data Protection and Privacy" of the HERA taxonomy, given that the app uses microphone and accelerometer data for sleep staging and uploads user data for personalisation? [card_cra · p.0]

### USER
We ask for microphone permission with an onboarding video plus a separate consent step, but honestly it's basically a single 'turn on the mic for sleep tracking' flow — we haven't built a granular consent screen that spells out the on-device vs cloud-digest split, and I'll admit most users probably just tap through it.

### ASSISTANT
Does the lack of granular consent for on-device processing versus cloud-based data uploads pose a risk under [P2.D3] "Post-Market Surveillance and Risk Management" and [P2.D4] "Data Protection and Privacy" of the HERA taxonomy, and what steps are needed to ensure compliance with ePrivacy Art. 5(3) and GDPR Art. 6(1)(a)? [card_eprivacy_terminal · p.0] [card_gdpr_art6 · p.0]

### USER
The on-device recording stays local and the cloud digest is auto-deleted after 30 days, and account deletion is supported; we rely on the platform's standard transport encryption and provider-managed encryption at rest, but I'll be honest, we haven't done a formal security audit or pen-test yet.

### ASSISTANT
Does the absence of a formal security audit or penetration test pose a risk under [P2.D3] "Post-Market Surveillance and Risk Management" and [P2.D4] "Data Protection and Privacy" of the HERA taxonomy, and what steps are needed to ensure compliance with the EU AI Act's requirements for high-risk systems and GDPR's data protection by design principles? [card_eu_ai_act · p.0] [card_gdpr_art30 · p.0]

### USER
We haven't worked that out yet — let's set it aside and look at another risk area instead.

### ASSISTANT
What is the potential risk to user safety and clinical effectiveness under [P1.D5] "Clinical Safety and Effectiveness" of the HERA taxonomy, given that the CBT-I coaching programme is not validated in-app and relies on published literature for its efficacy? [card_diga_germany · p.0]

### USER
We tell users it's a sleep-tracking and CBT-I coaching tool, but we don't yet have clear in-app messaging about what it can't do — for instance that it's not a diagnosis and that ~80% staging accuracy means some nights will be wrong.

### ASSISTANT
Does the lack of clear in-app messaging about the limitations of sleep staging accuracy and the non-diagnostic nature of the CBT-I coaching programme pose a risk under [P1.D5] "Clinical Safety and Effectiveness" and [P2.D4] "Data Protection and Privacy" of the HERA taxonomy, and what steps are needed to ensure compliance with GDPR Art. 5(1) and the EU AI Act's transparency requirements? [card_gdpr_art5 · p.0] [card_eu_ai_act · p.0]

### USER
Sleep staging accuracy ~80% vs polysomnography (in-lab study N=50).

### ASSISTANT
Does the 80% accuracy of sleep staging versus polysomnography, derived from an in-lab study with N=50, pose a risk under [P1.D5] "Clinical Safety and Effectiveness" of the HERA taxonomy, and what steps are needed to ensure compliance with the EU AI Act's transparency requirements and MDR Rule 11(b) for SaMD Class IIb devices? [card_eu_ai_act · p.0] [card_mdr_2017_745 · p.0]

### USER
CNN for sleep staging from audio + motion; rule-based CBT-I prescription engine.

### USER
Thanks for the conversation. Could you produce a brief structured risk report now? Use HERA dimension IDs (e.g. [P1.D2]) and group risks by severity. End the report with a list of dimensions you didn't get to cover.

### ASSISTANT
**HERA Risk & Safety Report for SleepWell mHealth App**  
*Based on current information and regulatory context in the EU*

---

### **High Severity Risks**  
1. **[P1.D5] Clinical Safety and Effectiveness**  
   - *Risk:* The CBT-I coaching programme lacks in-app validation and relies solely on published literature for efficacy. This undermines the clinical effectiveness and safety of the app, particularly for users seeking therapeutic outcomes.  
   - *Mitigation:* Conduct a clinical evaluation in line with MDR Rule 11(b) for SaMD Class IIb devices, including a clinical performance evaluation and PMCF plan to monitor real-world effectiveness. [mdr_2017_745 · p.0]  

2. **[P1.D2] Clinical Validity and Performance**  
   - *Risk:* Sleep staging accuracy of ~80% from an in-lab study with N=50 is insufficient to meet the clinical validity requirements for a Class IIb SaMD. This could mislead users about the accuracy of sleep tracking and affect the reliability of the CBT-I coaching.  
   - *Mitigation:* Perform a robust clinical evaluation in line with MDCG 2020-1, including analytical and clinical performance validation, and ensure transparency under the EU AI Act. [mdr_2017_745 · p.0]  

3. **[P2.D4] Data Protection and Privacy**  
   - *Risk:* The lack of granular consent for on-device vs cloud processing, combined with reliance on platform encryption without a formal security audit, could lead to data misuse or breaches.  
   - *Mitigation:* Implement a granular consent mechanism, conduct a formal security audit, and ensure compliance with GDPR Art. 6(1)(a) and the EU AI Act’s transparency requirements. [gdpr_art6 · p.0]  

4. **[P2.D3] Post-Market Surveillance and Risk Management**  
   - *Risk:* Relying on crash analytics and monthly retention reviews is insufficient for post-market monitoring under the EU AI Act (Art. 72) and MDR (Art. 84). This could delay identification of safety or performance issues.  
   - *Mitigation:* Establish a comprehensive PMS plan with PMCF tracking, including real-time monitoring of model performance and user feedback. [pms_lifecycle · p.0]  

---

### **Medium Severity Risks**  
1. **[P2.D5] Cybersecurity and Vulnerability Management**  
   - *Risk:* The absence of a Software Bill of Materials (SBOM) and coordinated-disclosure policy poses a risk under the CRA’s cybersecurity essential requirements.  
   - *Mitigation:* Develop an SBOM, implement a coordinated-disclosure policy, and conduct regular penetration testing. [cra · p.0]  

2. **[P1.D4] Human Oversight and Transparency**  
   - *Risk:* The lack of clear in-app messaging about the limitations of sleep staging and the non-diagnostic nature of the CBT-I programme could lead to user misunderstanding and misuse.  
   - *Mitigation:* Provide clear, user-friendly messaging about the app’s limitations, including accuracy rates and non-diagnostic status, in line with EU AI Act transparency requirements. [eu_ai_act · p.0]  

---

### **Low Severity Risks**  
1. **[P2.D6] User Education and Awareness**  
   - *Risk:* Users may not fully understand the app’s capabilities and limitations, especially if they tap through consent screens.  
   - *Mitigation:* Improve user education through onboarding and in-app messaging to ensure informed consent and awareness of the app’s intended use.  

---

### **Dimensions Not Covered**  
- [P1.D1] **Clinical Need and Intended Use**  
- [P1.D3] **Ethical Considerations**  
- [P2.D1] **Data Minimization and Purpose Limitation**  
- [P2.D2] **Data Retention and Deletion**  
- [P3.D1] **Ethical AI and Fairness**  
- [P3.D2] **User Autonomy and Control**  
- [P3.D3] **Transparency and Explainability**  

---

**Next Steps:**  
- Conduct a clinical evaluation for SaMD Class IIb compliance.  
- Implement granular consent and data protection measures.  
- Establish a robust PMS and cybersecurity framework.  
- Engage in a formal security audit and penetration test.  

Let me know if you’d like a mitigation plan for any of these risks.

Now produce the JSON judgement object.